desipramine

Overview
Prescribing Info
Drug Label Annotations
Clinical Annotations
Variant Annotations
Literature
Pathways
Related To
Links
Navigate to...
Show section selector dropdown

Literature

The publications shown below are associated with this chemical in PharmGKB based on (1) literature annotations, (2) variant annotations, (3) VIP summaries, or (4) pathways.

    71 items
    Literature
    A Comprehensive CYP2D6 Drug-Drug-Gene Interaction Network for Application in Precision Dosing and Drug Development.
    Clinical pharmacology and therapeutics. 2025. Rüdesheim Simeon, Loer Helena Leonie Hanae, Feick Denise, Marok Fatima Zahra, Fuhr Laura Maria, Selzer Dominik, Teutonico Donato, Schneider Annika R P, Solodenko Juri, Frechen Sebastian, van der Lee Maaike, Moes Dirk Jan A R, Swen Jesse J, Schwab Matthias and Lehr Thorsten.
    PGx Paper Type: Methods, Phenoconversion
    Literature
    Pharmacogenetics: Opportunities for the All of Us Research Program and Other Large Data Sets to Advance the Field.
    Annual review of pharmacology and toxicology. 2025. Empey Philip E, Karnes Jason H and Johnson Julie A.
    PGx Paper Type: Implementation, Review
    Literature
    Validating the accuracy of mathematical model-based pharmacogenomics dose prediction with real-world data.
    European journal of clinical pharmacology. 2025. Saab Yolande and Nakad Zahi.
    PGx Paper Type: Implementation, Methods
    Literature
    Association of Pharmacogenomic Phenotypes in CYP2D6, CYP2C9, CYP2C19, and CYP3A5 on Polypharmacy in Veterans.
    Clinical pharmacology and therapeutics. 2024. Krulikas Linas, Bates Jill, Chanfreau Catherine, Coleman Heather, Dalton Shawn and Voora Deepak.
    Literature
    Prescription medications with actionable pharmacogenomic recommendations in Veterans Health Administration patients.
    Pharmacogenomics. 2023. Maghari Saba, Gallo Tyler, Rivas Salvador, German Alexander, Nguyen Le Minh Q, Abbaszadegan Hamed, Zubriski Mark A, Heise Craig W and Landas Noel D.
    PGx Paper Type: Implementation
    Literature
    Identifying the prevalence of clinically actionable drug-gene interactions in a health system biorepository to guide pharmacogenetics implementation services.
    Clinical and translational science. 2023. Pasternak Amy L, Ward Kristen, Irwin Madison, Okerberg Carl, Hayes David, Fritsche Lars, Zoellner Sebastian, Virzi Jessica, Choe Hae Mi and Ellingrod Vicki.
    PGx Paper Type: Implementation
    Literature
    Opportunity for pharmacogenetics testing in patients with sickle cell anemia.
    Pharmacogenomics. 2022. Gallaway Katherine A, Sakon Colleen, Ongeri Jefney, Patel Krina S, Oliver Johnathan, Patacca Heather, O'Brien Andrew Rw, Skaar Todd C and Tillman Emma M.
    PGx Paper Type: Implementation
    Literature
    Identification of Drug Transporter Genomic Variants and Inhibitors That Protect Against Doxorubicin-Induced Cardiotoxicity.
    Circulation. 2022. Magdy Tarek, Jouni Mariam, Kuo Hui-Hsuan, Weddle Carly J, Lyra-Leite Davi, Fonoudi Hananeh, Romero-Tejeda Marisol, Gharib Mennat, Javed Hoor, Fajardo Giovanni, Ross Colin J D, Carleton Bruce C, Bernstein Daniel and Burridge Paul W.
    PGx Paper Type: Methods, Allele Function
    Literature
    Tools for optimising pharmacotherapy in psychiatry (therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests): focus on antidepressants.
    The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry. 2021. Eap C B, Gründer G, Baumann P, Ansermot N, Conca A, Corruble E, Crettol S, Dahl M L, de Leon J, Greiner C, Howes O, Kim E, Lanzenberger R, Meyer J H, Moessner R, Mulder H, Müller D J, Reis M, Riederer P, Ruhe H G, Spigset O, Spina E, Stegman B, Steimer W, Stingl J, Suzen S, Uchida H, Unterecker S, Vandenberghe F and Hiemke C.
    Literature
    The Pharmacogenomics Research Network Translational Pharmacogenetics Program: Outcomes and Metrics of Pharmacogenetic Implementations Across Diverse Healthcare Systems.
    Clinical pharmacology and therapeutics. 2017. Luzum J A, Pakyz R E, Elsey A R, Haidar C E, Peterson J F, Whirl-Carrillo M, Handelman S K, Palmer K, Pulley J M, Beller M, Schildcrout J S, Field J R, Weitzel K W, Cooper-DeHoff R M, Cavallari L H, O'Donnell P H, Altman R B, Pereira N, Ratain M J, Roden D M, Embi P J, Sadee W, Klein T E, Johnson J A, Relling M V, Wang L, Weinshilboum R M, Shuldiner A R, Freimuth R R and Pharmacogenomics Research Network Translational Pharmacogenetics Program.
    Literature
    Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update.
    Clinical pharmacology and therapeutics. 2017. Hicks J K, Sangkuhl K, Swen J J, Ellingrod V L, Müller D J, Shimoda K, Bishop J R, Kharasch E D, Skaar T C, Gaedigk A, Dunnenberger H M, Klein T E, Caudle K E and Stingl J C.
    PGx Paper Type: Implementation
    Literature
    Efficacy of prospective pharmacogenetic testing in the treatment of major depressive disorder: results of a randomized, double-blind clinical trial.
    BMC psychiatry. 2017. Pérez Víctor, Salavert Ariana, Espadaler Jordi, Tuson Miquel, Saiz-Ruiz Jerónimo, Sáez-Navarro Cristina, Bobes Julio, Baca-García Enrique, Vieta Eduard, Olivares José M, Rodriguez-Jimenez Roberto, Villagrán José M, Gascón Josep, Cañete-Crespillo Josep, Solé Montse, Saiz Pilar A, Ibáñez Ángela, de Diego-Adeliño Javier, AB-GEN Collaborative Group and Menchón José M.
    PGx Paper Type: Implementation
    Literature
    Pharmacogenetics of drug-drug interaction and drug-drug-gene interaction: a systematic review on CYP2C9, CYP2C19 and CYP2D6.
    Pharmacogenomics. 2017. Bahar Muh Akbar, Setiawan Didik, Hak Eelko and Wilffert Bob.
    Literature
    The Use of In Vitro Data and Physiologically-Based Pharmacokinetic Modeling to Predict Drug Metabolite Exposure: Desipramine Exposure in Cytochrome P4502D6 Extensive and Poor Metabolizers Following Administration of Imipramine.
    Drug metabolism and disposition: the biological fate of chemicals. 2016. Nguyen Hoa Q, Callegari Ernesto and Obach R Scott.
    Literature
    The genetics of pro-arrhythmic adverse drug reactions.
    British journal of clinical pharmacology. 2014. Petropoulou Evmorfia, Jamshidi Yalda and Behr Elijah R.
    Literature
    Challenges in pharmacogenetics.
    European journal of clinical pharmacology. 2013. Cascorbi Ingolf, Bruhn Oliver and Werk Anneke N.
    Literature
    Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants.
    Clinical pharmacology and therapeutics. 2013. Hicks J K, Swen J J, Thorn C F, Sangkuhl K, Kharasch E D, Ellingrod V L, Skaar T C, Müller D J, Gaedigk A, Stingl J C and Clinical Pharmacogenetics Implementation Consortium.
    PGx Paper Type: Implementation
    Literature
    Cytochrome P450-mediated drug metabolism in the brain.
    Journal of psychiatry & neuroscience : JPN. 2013. Miksys Sharon and Tyndale Rachel F.
    Literature
    Coprescription of tamoxifen and medications that inhibit CYP2D6.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010. Sideras Kostandinos, Ingle James N, Ames Matthew M, Loprinzi Charles L, Mrazek David P, Black John L, Weinshilboum Richard M, Hawse John R, Spelsberg Thomas C and Goetz Matthew P.
    Literature
    Beta2-adrenoceptors are essential for desipramine, venlafaxine or reboxetine action in neuropathic pain.
    Neurobiology of disease. 2009. Yalcin Ipek, Tessier Luc-Henri, Petit-Demoulière Nathalie, Doridot Stéphane, Hein Lutz, Freund-Mercier Marie-José and Barrot Michel.
    Literature
    Norepinephrine transporter regulation mediates the long-term behavioral effects of the antidepressant desipramine.
    Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2008. Zhao Zaorui, Baros Alicia M, Zhang Han-Ting, Lapiz M Danet S, Bondi Corina O, Morilak David A and O'Donnell James M.
    Literature
    An in vitro mechanistic study to elucidate the desipramine/bupropion clinical drug-drug interaction.
    Drug metabolism and disposition: the biological fate of chemicals. 2008. Reese Melinda J, Wurm Robert M, Muir Keith T, Generaux Grant T, St John-Williams Lisa and McConn Donavon J.
    Literature
    Genetic variants in FKBP5 affecting response to antidepressant drug treatment.
    Pharmacogenomics. 2008. Kirchheiner Julia, Lorch Rainer, Lebedeva Elena, Seeringer Angela, Roots Ivar, Sasse Johanna and Brockmöller Jürgen.
    Literature
    Prediction of pharmacokinetic drug-drug interactions using human hepatocyte suspension in plasma and cytochrome P450 phenotypic data. II. In vitro-in vivo correlation with ketoconazole.
    Drug metabolism and disposition: the biological fate of chemicals. 2008. Lu Chuang, Hatsis Panos, Berg Cicely, Lee Frank W and Balani Suresh K.
    Literature
    Association of graded allele-specific changes in CYP2D6 function with imipramine dose requirement in a large group of depressed patients.
    Molecular psychiatry. 2008. Schenk P W, van Fessem M A C, Verploegh-Van Rij S, Mathot R A A, van Gelder T, Vulto A G, van Vliet M, Lindemans J, Bruijn J A and van Schaik R H N.
    Literature
    Molecules that mediate mood.
    The New England journal of medicine. 2007. Thase Michael E.
    Literature
    LeuT-desipramine structure reveals how antidepressants block neurotransmitter reuptake.
    Science (New York, N.Y.). 2007. Zhou Zheng, Zhen Juan, Karpowich Nathan K, Goetz Regina M, Law Christopher J, Reith Maarten E A and Wang Da-Neng.
    Literature
    Tricyclic antidepressant pharmacology and therapeutic drug interactions updated.
    British journal of pharmacology. 2007. Gillman P K.
    Literature
    Phosphodiesterase genes are associated with susceptibility to major depression and antidepressant treatment response.
    Proceedings of the National Academy of Sciences of the United States of America. 2006. Wong Ma-Li, Whelan Fiona, Deloukas Panagiotis, Whittaker Pamela, Delgado Marcos, Cantor Rita M, McCann Samuel M and Licinio Julio.
    Literature
    Association of a corticotropin-releasing hormone receptor 1 haplotype and antidepressant treatment response in Mexican-Americans.
    Molecular psychiatry. 2004. Licinio J, O'Kirwan F, Irizarry K, Merriman B, Thakur S, Jepson R, Lake S, Tantisira K G, Weiss S T and Wong M-L.
    Literature
    Clinical implications of genetic polymorphism of CYP2D6 in Mexican Americans.
    Annals of internal medicine. 2004. Flores Deborah L, Alvarado Israel, Wong Ma-Li, Licinio Julio and Flockhart David.
    Literature
    Impact of CYP2D6 intermediate metabolizer alleles on single-dose desipramine pharmacokinetics.
    Pharmacogenetics. 2004. Furman Katherine D, Grimm David R, Mueller Toby, Holley-Shanks Rhonda R, Bertz Richard J, Williams Laura A, Spear Brian B and Katz David A.
    Literature
    Inducible cAMP early repressor regulates corticosterone suppression after tricyclic antidepressant treatment.
    The Journal of neuroscience : the official journal of the Society for Neuroscience. 2004. Conti Alana C, Kuo Yuo-Chen, Valentino Rita J and Blendy Julie A.
    Literature
    Association between norepinephrine transporter gene polymorphism and major depression.
    Neuropsychobiology. 2004. Ryu Seung-Ho, Lee Seung-Hwan, Lee Heon-Jeong, Cha Ji-Hyun, Ham Byung-Joo, Han Chang-Su, Choi Myoung-Jin and Lee Min-Soo.
    Literature
    Haplotype architecture of the norepinephrine transporter gene SLC6A2 in four populations.
    Journal of human genetics. 2004. Belfer Inna, Phillips Gabriel, Taubman Julie, Hipp Heather, Lipsky Robert H, Enoch Mary-Anne, Max Mitchell B and Goldman David.
    Literature
    Some aspects of genetic polymorphism in the biotransformation of antidepressants.
    Therapie. 2004. Brøsen Kim.
    Literature
    Inhibitory effects of tricyclic antidepressants (TCAs) on human cytochrome P450 enzymes in vitro: mechanism of drug interaction between TCAs and phenytoin.
    Drug metabolism and disposition: the biological fate of chemicals. 2002. Shin Jae-Gook, Park Ji-Young, Kim Min-Jung, Shon Ji-Hong, Yoon Young-Ran, Cha In-June, Lee Sang-Seop, Oh Se-Wook, Kim Sang-Woo and Flockhart David A.
    Literature
    The role of noradrenaline and selective noradrenaline reuptake inhibition in depression.
    European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. 2002. Brunello N, Mendlewicz J, Kasper S, Leonard B, Montgomery S, Nelson J, Paykel E, Versiani M and Racagni G.
    Literature
    Duplication of CYP2D6 predicts high clearance of desipramine but high clearance does not predict duplication of CYP2D6.
    European journal of clinical pharmacology. 2001. Bergmann T K, Bathum L and Brosen K.
    Literature
    Metabolism of desipramine in Japanese psychiatric patients: the impact of CYP2D6 genotype on the hydroxylation of desipramine.
    Pharmacology & toxicology. 2000. Shimoda K, Morita S, Hirokane G, Yokono A, Someya T and Takahashi S.
    Literature
    Science, medicine, and the future: Pharmacogenetics.
    BMJ (Clinical research ed.). 2000. Wolf C R, Smith G and Smith R L.
    Literature
    Inhibition of human hepatic cytochrome P4502E1 by azole antifungals, CNS-active drugs and non-steroidal anti-inflammatory agents.
    Xenobiotica; the fate of foreign compounds in biological systems. 1998. Tassaneeyakul W, Birkett D J and Miners J O.
    Literature
    Relationship between plasma desipramine levels, CYP2D6 phenotype and clinical response to desipramine: a prospective study.
    European journal of clinical pharmacology. 1997. Spina E, Gitto C, Avenoso A, Campo G M, Caputi A P and Perucca E.
    Literature
    Imipramine metabolism in relation to the sparteine oxidation polymorphism--a family study.
    Pharmacogenetics. 1996. Madsen H, Hansen T S and Brøsen K.
    Pediatric
    Literature
    Steady-state plasma concentrations of imipramine and desipramine in relation to S-mephenytoin 4'-hydroxylation status in Japanese depressive patients.
    Journal of clinical psychopharmacology. 1996. Koyama E, Tanaka T, Chiba K, Kawakatsu S, Morinobu S, Totsuka S and Ishizaki T.
    Literature
    Imipramine metabolism in relation to the sparteine and mephenytoin oxidation polymorphisms--a population study.
    British journal of clinical pharmacology. 1995. Madsen H, Nielsen K K and Brøsen K.
    Literature
    Metabolic disposition of imipramine in oriental subjects: relation to metoprolol alpha-hydroxylation and S-mephenytoin 4'-hydroxylation phenotypes.
    The Journal of pharmacology and experimental therapeutics. 1994. Koyama E, Sohn D R, Shin S G, Chiba K, Shin J G, Kim Y H, Echizen H and Ishizaki T.
    Literature
    The N-demethylation of imipramine correlates with the oxidation of S-mephenytoin (S/R-ratio). A population study.
    British journal of clinical pharmacology. 1993. Skjelbo E, Gram L F and Brøsen K.
    Pediatric
    Literature
    Polymorphic 2-hydroxylation of desipramine. A population and family study.
    European journal of clinical pharmacology. 1993. Dahl M L, Iselius L, Alm C, Svensson J O, Lee D, Johansson I, Ingelman-Sundberg M and Sjöqvist F.
    Pediatric
    Literature
    Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population.
    Clinical pharmacology and therapeutics. 1992. Dahl M L, Johansson I, Palmertz M P, Ingelman-Sundberg M and Sjöqvist F.
    Pediatric
    Literature
    Effect of fluoxetine on plasma desipramine and 2-hydroxydesipramine.
    Biological psychiatry. 1992. Suckow R F, Roose S P and Cooper T B.
    Literature
    Role of P450IID6, the target of the sparteine-debrisoquin oxidation polymorphism, in the metabolism of imipramine.
    Clinical pharmacology and therapeutics. 1991. Brøsen K, Zeugin T and Meyer U A.
    Literature
    2-Hydroxydesipramine and desipramine plasma levels and electrocardiographic effects in depressed younger adults.
    Journal of clinical psychopharmacology. 1991. Stern S L, Ribner H S, Cooper T B, Nelson L D, Johnson M H and Suckow R F.
    Literature
    The mephenytoin oxidation polymorphism is partially responsible for the N-demethylation of imipramine.
    Clinical pharmacology and therapeutics. 1991. Skjelbo E, Brøsen K, Hallas J and Gram L F.
    Literature
    Elevated antidepressant plasma levels after addition of fluoxetine.
    The American journal of psychiatry. 1989. Aranow A B, Hudson J I, Pope H G, Grady T A, Laage T A, Bell I R and Cole J O.
    Literature
    Therapeutic drug monitoring of tricyclic antidepressants.
    Clinical chemistry. 1988. Preskorn S H, Dorey R C and Jerkovich G S.
    Literature
    First-pass metabolism of imipramine and desipramine: impact of the sparteine oxidation phenotype.
    Clinical pharmacology and therapeutics. 1988. Brøsen K and Gram L F.
    Literature
    Differences in the inhibitory effect of cimetidine on desipramine metabolism between rapid and slow debrisoquin hydroxylators.
    Clinical pharmacology and therapeutics. 1987. Steiner E and Spina E.
    Literature
    Hydroxylation of desmethylimipramine: dependence on the debrisoquin hydroxylation phenotype.
    Clinical pharmacology and therapeutics. 1987. Spina E, Steiner E, Ericsson O and Sjöqvist F.
    Literature
    Imipramine demethylation and hydroxylation: impact of the sparteine oxidation phenotype.
    Clinical pharmacology and therapeutics. 1986. Brøsen K, Otton S V and Gram L F.
    Literature
    Steady-state concentrations of imipramine and its metabolites in relation to the sparteine/debrisoquine polymorphism.
    European journal of clinical pharmacology. 1986. Brøsen K, Klysner R, Gram L F, Otton S V, Bech P and Bertilsson L.
    Literature
    Desipramine and 2-hydroxydesipramine plasma levels in endogenous depressed patients. Lack of correlation with therapeutic response.
    Archives of general psychiatry. 1985. Amsterdam J D, Brunswick D J, Potter L, Winokur A and Rickels K.
    Pediatric
    Literature
    Phenotypic consistency in hydroxylation of desmethylimipramine and debrisoquine in healthy subjects and in human liver microsomes.
    Clinical pharmacology and therapeutics. 1984. Spina E, Birgersson C, von Bahr C, Ericsson O, Mellström B, Steiner E and Sjöqvist F.
    Literature
    The nonlinear kinetics of desipramine and 2-hydroxydesipramine in plasma.
    Clinical pharmacology and therapeutics. 1984. Cooke R G, Warsh J J, Stancer H C, Reed K L and Persad E.
    Pediatric
    Literature
    The debrisoquine hydroxylation test predicts steady-state plasma levels of desipramine.
    British journal of clinical pharmacology. 1983. Bertilsson L and Aberg-Wistedt A.
    Literature
    Desipramine plasma concentration and antidepressant response.
    Archives of general psychiatry. 1982. Nelson J C, Jatlow P, Quinlan D M and Bowers M B.
    Literature
    The clinical application of tricyclic antidepressant pharmacokinetics and plasma levels.
    The American journal of psychiatry. 1980. Amsterdam J, Brunswick D and Mendels J.
    Literature
    Single-dose kinetics predict steady-state concentrations on imipramine and desipramine.
    Archives of general psychiatry. 1980. Potter W Z, Zavadil A P, Kopin I J and Goodwin F K.
    Pediatric
    Literature
    CPIC® Guideline for Tricyclic Antidepressants and CYP2D6 and CYP2C19 – CPIC
    PGx Paper Type: Implementation
    Literature
    Drugs@FDA: Drug Product Norpramin (desipramine hydrochloride), NDA014399, sanofi-aventis U.S. LLC
    Literature
    Drugs@HCSC: Drug Product DESIPRAMINE (desipramine), AA PHARMA INC.